Article
Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens.
Pathology - 1 Jan 2017
Rathi Vivek, Wright Gavin, Constantin Diana, Chang Siok, Pham Huong, Jones Kerryn, Palios Atha, Mclachlan Sue-Anne, Conron Matthew, McKelvie Penny, Williams Richard
Abstract excerpt
The advent of massively parallel sequencing has caused a paradigm shift in the ways cancer is treated, as personalised therapy becomes a reality. More and more laboratories are looking to introduce next generation sequencing (NGS) as a tool for mutational analysis, as this technology has many advantages compared to conventional platforms like Sanger sequencing. In Australia all massively parallel sequencing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.